argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
The transaction pairs an upfront payment from cash on hand with additional payments contingent on development and regulatory milestones.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
argenx (ARGX) signed a definitive agreement to acquire Unnatural Products, adding peptide discovery capabilities to its immunology research platform. Already a minority shareholder, argenx will acquire all remaining shares. The terms include $550 million upfront from cash on hand and up to $595 million contingent on specified development and regulatory milestones, for total potential consideration of up to approximately $1.15 billion.
Both boards approved the transaction, which argenx expects to close by year-end, subject to customary closing conditions. The company sees potential to develop oral or long-acting medicines by pairing UNP’s macrocyclic peptides—ring-shaped molecules—with its antibody engineering. After closing, UNP’s current team and leadership will remain in Santa Cruz, California, and lead discovery within an agreed framework; argenx will provide clinical development and commercialization capabilities.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Definitive acquisition agreement would add UNP’s peptide discovery capabilities to argenx’s immunology platform.
- Minor point. Forward-looking: it has not happened yet and may not happen.Oral and long-acting medicines are potential development opportunities argenx identifies from combining peptide and antibody capabilities.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.$550 million upfront payment will use argenx’s cash on hand.
- Minor point. Forward-looking: it has not happened yet and may not happen.Up to $595 million in additional payments are contingent on specified development and regulatory milestones.
Key Figures
- Upfront payment
- $550 million
- Cash on hand
- Milestone payments
- Up to $595 million
- Contingent on specified development and regulatory milestones
- Total potential consideration
- Up to approximately $1.15 billion
- Acquisition of UNP
- Expected closing
- By the end of the year
- Subject to customary closing conditions
Key Terms
macrocyclic peptide technical
milestone payments financial
inside information regulatory
neonatal fc receptor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biology
- Extends argenx’s immunology innovation to more patients, with the potential for oral and long-acting medicines
- Builds on more than two years of collaboration and investment; UNP to continue operating from Santa Cruz, California with its current team, preserving the science-first culture behind its success
Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately
“Our ambition is to be the leading immunology innovation company, and as argenx builds its next chapter, we are investing with discipline where it will count the most for patients,” said Karen Massey, Chief Executive Officer of argenx. “UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines. After working together for more than two years, we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients. We want to preserve what has made UNP successful while bringing the strengths of both teams together.”
“Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters,” said Cameron Pye, Ph.D., CEO and Co-Founder of UNP. “From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines. I am so proud of what our team has accomplished and believe argenx provides the ideal environment to accelerate and amplify that vision to bring innovative therapies to patients.”
Following closing of the acquisition, UNP’s team and leadership will continue to operate from its Santa Cruz, California site, which will serve as argenx’s home for peptide discovery. UNP will continue to lead its discovery work, within a strategic framework agreed upon with argenx. argenx will bring its clinical development and commercialization capabilities to advance those medicines to patients.
Transaction Terms
Under the terms of the agreement, argenx will acquire UNP for an upfront payment of
The boards of directors of both companies have approved the transaction. The acquisition is expected to close by the end of the year, subject to customary closing conditions.
Advisors
Morgan Stanley & Co. LLC is serving as exclusive financial advisor and DLA Piper LLP is serving as legal advisor to argenx. Latham & Watkins LLP is serving as legal counsel to UNP.
About argenx
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early- and late-stage programs across several therapeutic areas. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
About Unnatural Products, Inc.
Unnatural Products, Inc. (UNP), a Santa Cruz, California-based biotech company, has developed a platform that addresses the complexities of medicinal chemistry in the macrocyclic peptide space through a combination of parallel experimentation and machine learning. Founded by macrocycle pioneers whose academic work uncovered how nature’s macrocycles work, UNP is developing a portfolio of therapeutic macrocycles against high-value and traditionally difficult-to-drug targets.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).
Contacts:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
Forward Looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements generally can be identified by the use of forward-looking words, such as “believe”, “can”, “continue”, “expect”, “possible”, “potential”, “seek”, “target”, “will”, “pursue” and other words and terms of similar meaning and expression, including in connection with any discussion of future operating or financial performance. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. These statements are based on the current expectations, estimates and assumptions of the management of argenx and UNP regarding future events, and on information currently available to them. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations of argenx or UNP.
All statements contained in this press release other than statements of historical fact are, or may be deemed to be, forward-looking statements, including, without limitation, statements regarding the transaction and other related matters, including the expected timing of the closing of the transaction, the ability of the parties to complete the transaction and to satisfy the conditions to its consummation, and the possibility of any termination of the definitive agreement; the expected benefits and opportunities of the transaction, including the potential achievement of the development and regulatory milestones and the making of any related contingent payments; the expected funding of the transaction; prospective performance and opportunities; post-closing operations, the integration of UNP and the outlook for the businesses of UNP and argenx, including, without limitation, results from clinical trials, regulatory applications and related timelines and the ability of argenx to advance UNP’s product pipeline; and any assumptions underlying any of the foregoing.
Actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, uncertainties as to the timing of the transaction; the risk that the transaction may not be completed in a timely manner or at all; the possibility that any or all of the various conditions to the consummation of the transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement; the effect of the announcement or pendency of the transactions contemplated by the definitive agreement on argenx’s business; the risk that the expected benefits and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; risks and uncertainties related to argenx’s ability to successfully integrate UNP’s programs, technologies, employees and operations; the uncertainty of whether, when and to what extent the development and regulatory milestones will be achieved and any related contingent payments will become payable; having to use cash in ways other than as expected; challenges inherent in product research and development, including uncertainty of preclinical and clinical success and of obtaining regulatory approvals; and other risks related to the businesses of argenx and UNP generally.
A further list and description of these and other risks, uncertainties, and factors that could cause actual results to differ materially from those referred to in the forward-looking statements can be found in argenx’s SEC filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these risks and uncertainties, the reader is advised not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. Neither argenx nor UNP undertakes any obligation to publicly update or revise the information in this press release, including any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much will argenx pay to acquire Unnatural Products?
The terms include $550 million upfront from cash on hand and up to $595 million in payments contingent on specified development and regulatory milestones. Total potential consideration is up to approximately $1.15 billion. argenx already holds a minority stake and will acquire all remaining shares.
When is argenx expected to close the Unnatural Products acquisition?
argenx expects the acquisition to close by the end of 2026, subject to customary closing conditions. The boards of directors of both companies have approved the transaction.